Healthcare - Biotechnology - NASDAQ - US
$ 3.38
2.42 %
$ 3.53 M
Market Cap
-0.23
P/E
CASH FLOW STATEMENT
-13.4 K
OPERATING CASH FLOW
399 K
INVESTING CASH FLOW
-3.73 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pasithea Therapeutics Corp.
| Net Income | -15.5 M |
| Depreciation & Amortization | 648 K |
| Capital Expenditures | -34.3 |
| Stock-Based Compensation | 592 K |
| Change in Working Capital | 1.57 M |
| Others | -1.06 B |
| Free Cash Flow | -13.5 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (15.5) | (13.9) | (2.2) | 41 K |
| Depreciation & Amortization | 0.6 | 32.4 K | 1.38 K | 0 |
| Deferred Income Tax | 0 | 0 | (2.3) | 0 |
| Stock Based Compensation | 0.6 | 0.8 | 0.5 | 0 |
| Other Operating Activities | 12.7 | (1.1) | 0.8 | 9.9 K |
| Change in Working Capital | 1.6 | (0.1) | 0.1 | 2.3 K |
| Cash From Operations | 13.4 K | (14.6) | (3.2) | 38.7 K |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | 34.3 | (2.1) | 21.5 K | 0 |
| Other Items | 0.4 | 77.1 K | 0 | 0 |
| Cash From Investing Activities | 0.4 | (2.1) | 21.5 K | 0 |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | (3.7) | (3.2) | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 3.21 K | 5.7 | 0.3 |
| Cash From Financing Activities | (3.7) | (3.2) | 55.9 | 0.3 |
| CHANGE IN CASH | ||||
| Net Change In Cash | (16.8) | (19.8) | 52.7 | 0.2 |
| FREE CASH FLOW | ||||
| Free Cash Flow | (13.5) | (16.7) | (3.2) | 38.7 K |